Rachel received her BSE in chemical engineering at the University of Michigan. She is currently pursuing a PhD in molecular engineering with an emphasis on immunoengineering.
Rachel's research at the University of Michigan involved modeling nanoparticle drug-delivery systems for targeted chemotherapy. Her current research interests in the Hubbell Lab involve developing technology to induce immunological tolerance for treating transplant rejection and autoimmune disorders.